Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML

Firas El Chaer, Uma Borate, Rémy Duléry, Shernan G. Holtan, Arjun Datt Law, Lori Muffly, Samah Nassereddine, Rory M. Shallis, Kate Stringaris, Justin Taylor, Steven M. Devine, Mohamad Mohty, Christopher S. Hourigan

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish (US)
Pages (from-to)1757-1759
Number of pages3
JournalBlood Advances
Volume5
Issue number6
DOIs
StatePublished - Mar 23 2021

Bibliographical note

Funding Information:
Conflict-of-interest disclosure: U.B. has served as a consultant for Genentech and Bristol Myers Squibb and has research funding from Astellas. S.G.H. has served as a consultant for Incyte, Bristol Myers Squibb, and Generon. L.M. has research funding from Jasper, Adaptive, Astellas, and Servier and has served as a consultant for Pfizer and Amgen. The remaining authors declare no competing financial interests.

Funding Information:
Acknowledgments: This work was supported in part by the Intramural Research Program of the National Heart, Lung, and Blood Institute, National Institutes of Health (grant 1ZIAHL006163).

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Intramural

Cite this